SUSTAINED EFFECT OF SERALUTINIB ON CIRCULATING BIOMARKERS IN THE TORREY PHASE 2 OPEN-LABEL EXTENSION STUDY

SUSTAINED EFFECT OF SERALUTINIB ON CIRCULATING BIOMARKERS IN THE TORREY PHASE 2 OPEN-LABEL EXTENSION STUDY

PVRILatam – Nov 2024a

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study